Across TCGA pan-cancer cohorts, TXN mass-spec protein is linked to patient survival in 3 of 34 cancer types, making it a survival-associated TXN data layer compared with 25 for mass-spec protein.
The strongest signal is observed in glioblastoma multiforme (GBM), where higher TXN mass-spec protein is associated with better overall survival. In most high-consensus cancer types, elevated TXN expression acts as an unfavorable survival marker, although some lineages such as GBM and LSCC show a favorable association.
GBM, LSCC, and LUAD are the cancer types where TXN mass-spec protein most reproducibly stratifies survival.